



Ref: Syn/CS/SE/BM/2025-26/Apr/11

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 23, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Intimation under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you that, based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors at its meeting held today (i.e. Wednesday, April 23, 2025) have *inter-alia* considered and approved the

- appointment of Dr. Sanjaya Singh as an Additional Director (Independent, Non-Executive) with effect from July 1, 2025 until the Annual General Meeting to be held in the year 2028, subject to the approval of the shareholders
- appointment of Mr. Suresh Narayanan (DIN: 07246738) as an Additional Director (Independent, Non-Executive) with effect from August 1, 2025 until the Annual General Meeting to be held in the year 2028, subject to the approval of the shareholders
- resignation of Ms. Priyadarshini Mahapatra, Head Legal, Company Secretary & Compliance Officer (Key Managerial Personnel) from the services of the Company. Her last working date with the Company would be June 9, 2025. The Company places on record its sincere appreciation and gratitude for her exemplary services and invaluable contributions.

As per SEBI letter dated June 14, 2018 read along with NSE Circular dated June 20, 2018, having ref no. as - NSE/CML/2018/24, we hereby confirm that Dr. Sanjaya Singh and Mr. Suresh Narayanan are not debarred from holding the office of director by virtue of any order of SEBI or any other authority. The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure A**.



The above information will also be available on the website of the Company at www.syngeneintl.com.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Deepak Jain
Chief Financial Officer

Encl: as above

The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. No.	Particulars	Dr. Sanjaya Singh	Mr. Suresh Narayanan	Ms. Priyadarshini Mahapatra
1	Reason for Change viz. appointment, re-appointment , resignation, removal , death or otherwise	Appointment as an Additional Director (Independent, Non-Executive).	Appointment as an Additional Director (Independent, Non-Executive).	Resignation from the position of Head Legal, Company Secretary & Compliance Officer; and Key Managerial Personnel of the Company to pursue other career opportunities.
2	Date of appointment and term of appointment	Effective from July 1, 2025	Effective from August 1, 2025	Effective from June 09, 2025
3	Brief Profile (in case of appointment of a Director)	Sanjaya Singh is the Founder and Chief Scientific Officer of Third Arc Bio, with over 25 years of expertise in biotherapeutics. He has a proven track record of innovation across multiple therapeutic areas, including immunology, oncology, retinal, metabolic, and neurological diseases. Throughout his career, he has developed novel biologics, many of which have received FDA breakthrough designations. He is a co-inventor of several key molecules, including SKYRIZI®, EBGLYSS™, PRAXBIND®, ligelizumab, and lampalizumab.	With over three decades of extensive experience in the FMCG industry, Mr. Narayanan has held senior leadership roles across geographies, driving growth and transformation in global markets. Mr. Suresh Narayanan has been serving as the Chairman and Managing Director of Nestlé India Limited since October 29, 2015. He first joined the company's Board of Directors as Managing Director on August 1, 2015. He holds a Master's degree in Economics from the Delhi School of Economics, a Diploma in Executive Development from IMD, and is an	Not applicable

		<p>Previously, Sanjaya served as Head of Janssen Biotherapeutics, where he led the global therapeutics discovery organization and set the strategic direction for expanding Johnson & Johnson's biotherapeutic portfolio. Prior to this, he was Vice President of Biotherapeutics Discovery at Boehringer Ingelheim, where he built and led a global team to establish a competitive and productive preclinical and clinical pipeline. Sanjaya began his industry career at Tanox Inc., where he headed Biotherapeutics until the company was acquired by Genentech.</p> <p>In addition to his leadership roles, Sanjaya co-founded Aliada Therapeutics, a neuroscience and blood-brain barrier platform company recently acquired by AbbVie. He also serves as a Venture Partner at Omega Funds, a prominent life sciences investment firm. His early career includes academic experience at the Institute of Life Sciences in India.</p>	<p>alumnus of the Nestlé Leadership Program at the London Business School.</p> <p>Before his appointment in India, Mr. Narayanan served as Chairman and CEO of Nestlé Philippines, where he played a key role in strengthening the business and its market presence. He began his journey with Nestlé in 1999 as Executive Vice President – Sales, India, where he led significant strategic and structural changes in sales and customer management, including the launch of the company's chilled dairy business.</p> <p>Mr. Narayanan began his professional career as a Management Trainee with Hindustan Unilever, subsequently taking on a range of roles in Sales, Marketing, and General Management. He also held key positions at Colgate-Palmolive India prior to joining Nestlé.</p> <p>A dynamic and people-focused leader, Mr. Narayanan is widely</p>	
--	--	--	---	--

		<p>Sanjaya has authored numerous peer-reviewed publications and holds over 60 patents, with contributions spanning basic research, platform technologies, and biologic molecules.</p> <p>Sanjaya earned his Ph.D. in Molecular Biology from Banaras Hindu University and completed postdoctoral research at University of Texas MD Anderson Cancer Center.</p>	<p>respected for his integrity, strategic foresight, and inclusive leadership style.</p>	
4	Disclosure of relationships between Directors (in case of appointment of Director)	None.	None.	Not applicable